t-cell engaging treatment in aml
Published 7 years ago • 521 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
0:37
the mechanism of treatment resistance in aml: do cd8-expressing t-cells become exhausted?
-
1:24
t-cell engaging antibodies: what lessons have we learnt?
-
3:01
t-cell engaging antibodies: novel combinations to overcome resistance
-
1:10
target antigens for t-cell engager therapies in all and aml
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
2:22
t-cell bispecifics in aml: ongoing challenges and future outlooks
-
1:59
t-cell engagers vs monoclonal antibodies for the treatment of aml: the influence of cd38 expression
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
43:38
webinar - bispecific antibodies: the next generation of antibody therapeutics
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
4:54
introduction to nk cell immunotherapy with inkmune - priming nk cells
-
1:31
pegenzileukin for t-cell dysfunction
-
1:05
t-cell evolution in aml and its impact on the efficacy of bispecific antibodies
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
3:27
the mechanism of bispecific t-cell engagers in b-all: genomic alterations
-
1:04
t-cell bispecific antibody targeting intracellular wt1 in aml
-
3:47
the role of immunotherapy in the aml treatment landscape
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
3:37
the future of aml treatment
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
1:25
the management of cll in italy